Gilead Sciences, INC.
Forward trial catalysts linked to GILD
CSA tracks 3 forward catalysts for Gilead Sciences, INC. across 1 asset, spanning Phase 3. The nearest is a readout expected Dec 2026 (month precision). Confidence across its tracked catalysts breaks down as 3 medium. Tracked indications include Metastatic Breast Cancer, Non-Small Cell Lung Cancer, Triple Negative Breast Cancer, and 2 more.
GILD in the full snapshot
The free sample on this page is a slice. In the current full CSA snapshot, Gilead Sciences, INC. has:
Forward catalysts by year
Every catalyst in the snapshot comes with its date, date confidence and source link.
7 trials behind these assets
| Asset | Trial | Phase | Status | Primary completion | Role | Lead sponsor | Condition(s) |
|---|---|---|---|---|---|---|---|
| sacituzumab govitecan hziy | NCT05089734 | Phase 3 | Active, not recruiting | 2023-11-29 | Experimental | Gilead Sciences | Non-Small Cell Lung Cancer |
| sacituzumab govitecan hziy | NCT04639986 catalyst | Phase 3 | Active, not recruiting | 2026-12 | Experimental | Gilead Sciences | Metastatic Breast Cancer |
| sacituzumab govitecan hziy | NCT05382286 catalyst | Phase 3 | Active, not recruiting | 2027-02 | Experimental | Gilead Sciences | Triple Negative Breast Cancer; PD-L1 Positive |
| sacituzumab govitecan hziy | NCT05633654 catalyst | Phase 3 | Recruiting | 2027-06 | Experimental | Gilead Sciences | Triple Negative Breast Cancer |
| sacituzumab govitecan hziy | NCT05840211 | Phase 3 | Active, not recruiting | 2028-04 | Experimental | Gilead Sciences | Locally Advanced or Unresectable Metastatic Breast Cancer; Stage IV Breast Cancer |
| sacituzumab govitecan hziy | NCT05382299 | Phase 3 | Active, not recruiting | 2028-07 | Experimental | Gilead Sciences | Triple Negative Breast Cancer; PD-L1 Negative |
| sacituzumab govitecan hziy | NCT06486441 | Phase 3 | Active, not recruiting | 2029-06 | Experimental | Gilead Sciences | Endometrial Cancer |
Every trial the CSA sample links to GILD's tracked assets.
Conditions studied
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This sponsor's catalysts are a slice of the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.
Get the full dataset — $499 →